Trial Profile
A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2024.
- 06 Oct 2022 Status changed from active, no longer recruiting to recruiting.
- 04 Oct 2022 Planned primary completion date changed from 1 Sep 2023 to 1 Dec 2023.